@medpagetoday.comTwo investigational anti-B7-H3 antibody-drug conjugates significantly improved survival outcomes in patients with relapsed small-cell lung cancer, according to a pair of Chinese trials. #WCLC26 @iaslc.bsky.social https://www.medpagetoday.com/meetingcoverage/iaslc/122982
@medpagetoday.comSurvival in metastatic NSCLC did not improve with the addition of the antibody-drug conjugate sacituzumab govitecan (Trodelvy) to immunotherapy, a large randomized trial showed. #WCLC26 @iaslc.bsky.social @drgreeklungcancer.bsky.social
https://www.medpagetoday.com/meetingcoverage/iaslc/122983
@cancertherapyadv.bsky.socialNew data from #WCLC26 found adding intercalating gefitinib to adjuvant platinum-based chemotherapy is associated with improved DFS for EGFR-altered #NSCLC! @iaslc.bsky.social 🫁
Read the full article: https://bit.ly/4xnnn9g
@lcrf.orgAmong those presenting today at #WCLC26 in Seoul, South Korea: LCRF Team Science grantee Dr. David Barbie; LCRF Scientific Advisory Board member Dr. Misako Nagasaka; and LCRF Education + Engagement Committee member Dr. Eric Singhi (twice).
#LungCancer @lungoncdoc.bsky.social
@lcrf.orgAmong those presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF grantees Dr. Jaime Schneider, Dr. Hilary Robbins, Dr. Benjamin Lok, and Dr. Christian Rolfo (twice!).
@oncoalert.bsky.social🚨 Could B7-H3 targeting represent a meaningful new direction in relapsed small-cell lung cancer? #WCLC26
👉 NEJM Article
www.nejm.org/doi/full/10....
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
@gsk.com#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer.
Learn more: gsk.to/4cJsjhu
@mskdeptofmed.bsky.socialDon't miss this #WCLC26 Presidential Symposium: @mskcancercenter.bsky.social lung cancer expert Dr. Alexander Drilon will present efficacy & safety data on a treatment for TKI-naive advanced ROS1+ non-small cell lung cancer.
September 14, 2026, at 9:38 a.m. KST
Details here: https://bit.ly/4xKYjtW
@lcrf.orgPresenting today at the World Conference on Lung Cancer: LCRF grantee Dr. William Feng.
Read more about his research at LCRF.org/FengUpdate.
@lungcancereurope.bsky.socialBetter #lungcancer diagnosis needs collaboration across the whole pathway.
At #WCLC26, our VP presented collaborative work with Lung Cancer Policy Network work drawing on evidence, 12 expert interviews and contributions from multidisciplinary members. #LCSM
@lcrf.orgAmong those presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF Scientific Advisory Board members Dr. Christine Lovly and Dr. Karen Reckamp; and LCRF grantees Dr. William Feng and Dr. Jamie Chaft.
@lcrf.orgAmong those presenting today at #WCLC26 in Seoul, South Korea: LCRF Education + Engagement Committee members Drs. Stephen Liu and Eric Singhi; LCRF Team Science grantee Dr. Elaine Shum; and LCRF Together Chicago panelist Dr. Jyoti Patel.
#LungCancer @stephenvliu.bsky.social @lungoncdoc.bsky.social
@lungcancereurope.bsky.social🧠 Phase 3 MAVERICK results at #WCLC26 could change care for small cell #lungcancer.
MRI surveillance alone protected cognitive outcomes vs adding preventive brain radiotherapy, with no significant diff in survival so far.
If confirmed, this could spare some people with #SCLC unnecessary treatment.
@gsk.com#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline.
Learn more: gsk.to/4xrKoZ1
@nejm.orgAmong patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: https://nej.md/4xKtvcF
@aacrjournals.bsky.socialRead the Hot Topics article collections, featuring impactful, cutting-edge research published in the AACR Journals: buff.ly/l0WH2jW #WCLC26
@lcrf.orgPresenting today at #WCLC26 in Seoul: LCRF grantees Drs. Hilary Robbins (twice!) and Xiuning Le; Education + Engagement Committee members Drs. Stephen Liu, Eric Singhi, & Narjust Florez; & Scientific Advisory Board member Dr. Roy Herbst.
#LungCancer @lungoncdoc.bsky.social @stephenvliu.bsky.social
@foundationmedicine.bsky.socialAt #WCLC26, we're excited to highlight 2 new posters: one on the clinical impact of NGS & targeted therapy across NSCLC histologic subtypes; the other analyzing homozygous losses & outcomes w/ standard of care treatment. Hear more from our team at booth 726. Learn more: spkl.io/633257utR1
@cancers-mdpi.bsky.socialLive from #WCLC26! 📸 Our team is all set at Booth #706. Drop by to connect, share insights, and discuss the latest in lung cancer research. We’d love to meet you! 💞
#IASLC #LungCancer #WCLC2026 @iaslc.bsky.social
@vslim.bsky.social